Certara Products - Simcyp Archives | Page 20 of 22

Publication

Application of Permeability-limited Physiologically-based Pharmacokinetic Models: Part I—Digoxin Pharmacokinetic Incorporating P-glycoprotein-mediated Efflux

A prerequisite for the prediction of the magnitude of P-glycoprotein (P-gp)-mediated drug-drug interactions between digoxin…

CertaraSeptember 1, 2013

Publication

Application of Permeability-limited Physiologically-based Pharmacokinetic Models: Part II—Prediction of P-glycoprotein Mediated Drug-drug Interactions with Digoxin

Digoxin is the recommended substrate for assessment of P-glycoprotein (P-gp)-mediated drug-drug interactions (DDIs) in vivo.…

CertaraSeptember 1, 2013

Publication

Application of In Vitro-In Vivo Extrapolation (IVIVE) and Physiologically-based Pharmacokinetic Modeling to Investigate the Impact of the CYP2C8 Polymorphism on Rosiglitazone Exposure

The purpose of this study was to predict the impact of the CYP2C8*3 genotype on…

CertaraJune 1, 2013

Publication

Physiologically-based Pharmacokinetic Models for Everolimus and Sorafenib in Mice

Everolimus is a mammalian target of rapamycin (mTOR) inhibitor approved as an immunosuppressant and for…

CertaraMay 1, 2013

Publication

A Physiologically-based Pharmacokinetic Modeling Approach to Predict Disease-drug Interactions: Suppression of CYP3A by IL-6

Elevated cytokine levels are known to downregulate expression and suppress activity of cytochrome P450 enzymes…

CertaraApril 10, 2013

Publication

Predicting Drug-drug Interactions: Application of Physiologically-based Pharmacokinetic Models Under a Systems Biology Approach

The development of in vitro-in vivo extrapolation (IVIVE), a 'bottom-up' approach, to predict pharmacokinetic parameters…

CertaraMarch 1, 2013

Publication

Pharmacokinetics, Pharmacodynamics, Physiologically-based Pharmacokinetic Modeling of Monoclonal Antibodies

Development of monoclonal antibodies (mAbs) and their functional derivatives represents a growing segment of the…

CertaraFebruary 1, 2013

Publication

Optimal Sampling Times for a Drug and Its Metabolite Using Simcyp Simulations as Prior Information

Since 2007, it is mandatory for the pharmaceutical companies to submit a Pediatric Investigation Plan…

CertaraJanuary 1, 2013

Publication

Application of PBPK Modeling to Predict Monoclonal Antibody Disposition in Plasma and Tissues in Mouse Models of Human Colorectal Cancer

This investigation evaluated the utility of a physiologically based pharmacokinetic (PBPK) model, which incorporates model…

CertaraDecember 1, 2012

Publication

A Pregnancy Physiologically-based Pharmacokinetic (p-PBPK) Model for Disposition of Drugs Metabolized by CYP1A2, CYP3A4, and CYP2D6

Pregnant women are usually not part of the traditional drug development program. Pregnancy is associated…

CertaraOctober 9, 2012

Certara Products – Simcyp

Application of Permeability-limited Physiologically-based Pharmacokinetic Models: Part I—Digoxin Pharmacokinetic Incorporating P-glycoprotein-mediated Efflux

Application of Permeability-limited Physiologically-based Pharmacokinetic Models: Part II—Prediction of P-glycoprotein Mediated Drug-drug Interactions with Digoxin

Application of In Vitro-In Vivo Extrapolation (IVIVE) and Physiologically-based Pharmacokinetic Modeling to Investigate the Impact of the CYP2C8 Polymorphism on Rosiglitazone Exposure

Physiologically-based Pharmacokinetic Models for Everolimus and Sorafenib in Mice

A Physiologically-based Pharmacokinetic Modeling Approach to Predict Disease-drug Interactions: Suppression of CYP3A by IL-6

Predicting Drug-drug Interactions: Application of Physiologically-based Pharmacokinetic Models Under a Systems Biology Approach

Pharmacokinetics, Pharmacodynamics, Physiologically-based Pharmacokinetic Modeling of Monoclonal Antibodies

Optimal Sampling Times for a Drug and Its Metabolite Using Simcyp Simulations as Prior Information

Application of PBPK Modeling to Predict Monoclonal Antibody Disposition in Plasma and Tissues in Mouse Models of Human Colorectal Cancer

A Pregnancy Physiologically-based Pharmacokinetic (p-PBPK) Model for Disposition of Drugs Metabolized by CYP1A2, CYP3A4, and CYP2D6

Newsletter sign up

Quick links

Solutions

Contact